Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background: The observed association between pioglitazone and bladder cancer could be causal or because of bias in the design of prior studies. We hypothesize that proteinuria testing may lead to detection bias if routine test results for proteinuria lead to a full urinalysis. Methods: We reanalyzed patients with diabetes mellitus within Kaiser Permanente Northern California. Logistic and Cox regression adjusted for age, sex, race, and smoking were used to assess the association of proteinuria testing with pioglitazone use, subsequent full urinalysis, and diagnosis with bladder cancer. Results: Patients treated with pioglitazone were more likely than others with diabetes to undergo testing for proteinuria (p < 0.001). The odds of positive tests for proteinuria were higher among pioglitazone‐treated patients (OR = 1.41, 95%CI 1.36–1.46). A positive proteinuria test was associated with increased odds of completing a urinalysis in the following 6 months (OR = 1.78, 95%CI 1.73–1.85). Negative and positive proteinuria test results were inversely (hazard ratio (HR) 0.63, 95%CI 0.52–0.75) and positively associated (HR 2.45, 95%CI 2.12–2.82) with bladder cancer risk, respectively. Adjustment for negative and positive proteinuria testing reduced the magnitude of association between pioglitazone and bladder cancer by only 5 to 10% (ever‐exposed HR: from 1.06 to 1.01 and >4 years exposure HR: from 1.38 to 1.28). Conclusions: Proteinuria testing may be a confounder in studies of pioglitazone and bladder cancer but does not fully explain the association between pioglitazone and bladder cancer in this cohort. Optimal adjustment for proteinuria testing likely requires knowledge of the test result. Copyright © 2014 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone
Lewis, J. D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W. B., Quesenberry, C. P., Vaughn, D. J., Nessel, L., Selby, J., & Strom, B. L. (2011) · Diabetes Care · doi:10.2337/dc10-1068 · Cited by 625
Self-citation
Cited by
Obesity and diabetes: the increased risk of cancer and cancer-related mortality
Gallagher, E. J., & LeRoith, D. (2015) · Physiological Reviews · doi:10.1152/physrev.00030.2014 · Cited by 806
“Further data have been uploaded to the European Medicines Agency’s European Network of Centers for Pharmacoepidemiology and Pharmacovigilance (ENCePP) website, and report that the increased risk of bladder cancer may have been due to a detection bias, due to increased urinary screening of patients with albuminuria, an…”
MethodThiazolidinediones and the promise of insulin sensitization in type 2 diabetes
Soccio, R. E., Chen, E. R., & Lazar, M. A. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.08.005 · Cited by 518
Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes
Lewis, J. D., Habel, L. A., Quesenberry, C. P., Strom, B. L., Peng, T., Hedderson, M. M., Ehrlich, S. F., Mamtani, R., Bilker, W., Vaughn, D. J., et al. (2015) · JAMA · doi:10.1001/jama.2015.7996 · Cited by 320
Self-citationPioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis
on behalf of the Scottish Diabetes Research Network Epidemiology Group and the Diabetes and Cancer Research Consortium, Levin, D., Bell, S., Sund, R., Hartikainen, S. A., Tuomilehto, J., Pukkala, E., Keskimäki, I., Badrick, E., Renehan, A. G., et al. (2015) · Diabetologia · doi:10.1007/s00125-014-3456-9 · Cited by 158
Gluud, L. L., Knop, F. K., & Vilsbøll, T. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-005325 · Cited by 59
Metadata
- Authors
- Lewis, J. D., Habel, L., Quesenberry, C., Mamtani, R., Peng, T., Bilker, W. B., Hedderson, M., Nessel, L., Vaughn, D. J., Strom, B. L., & Ferrara, A.
- Venue
- Pharmacoepidemiology and Drug Safety
- Publisher
- Wiley
- Published
- 2014-04-25
- Volume
- 23
- Issue
- 6
- Pages
- 636-645
- ISSN
- 1053-8569 (ISSN-L)
- 1099-1557
- OpenAlex
- W1960825336
- Cited by
- 27
- References
- 1
- FWCI
- 4.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer. https://app.cochat.ai/papers/10.1002/pds.3619
- The paper
- Lewis, J. D., Habel, L., Quesenberry, C., Mamtani, R., Peng, T., Bilker, W. B., Hedderson, M., Nessel, L., Vaughn, D. J., Strom, B. L., & Ferrara, A. (2014). Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.3619
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.